Rachelle Suzanne Jacques Sells 1,993 Shares of uniQure (NASDAQ:QURE) Stock

Posted by Stanley Muller on Jun 14th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Rachelle Suzanne Jacques sold 1,993 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the transaction, the director directly owned 33,903 shares in the company, valued at approximately $917,415.18. The trade was a 5.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

uniQure Trading Up 2.8%

NASDAQ:QURE opened at $27.57 on Friday. The firm has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock’s 50 day simple moving average is $22.52 and its 200-day simple moving average is $21.80. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE – Get Free Report) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Equities analysts anticipate that uniQure N.V. will post -3.64 EPS for the current year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Analysts Set New Price Targets

A number of brokerages recently weighed in on QURE. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $15.00 to $60.00 in a report on Monday, March 9th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday, May 5th. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, uniQure has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Read Our Latest Stock Report on uniQure

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. State Street Corp boosted its position in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC boosted its position in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in uniQure during the fourth quarter worth $33,062,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.